Previous 10 | Next 10 |
Yesterday, Jazz Pharmaceuticals (JAZZ) filed a complaint in Delaware federal court against Avadel Pharmaceuticals (AVDL) regarding an alleged infringement of five patents linked to the company’s blockbuster therapy Xyrem.The FDA application sought by Avadel to market its narcolepsy dru...
Image source: The Motley Fool. Avadel Pharmaceuticals plc (NASDAQ: AVDL) Q1 2021 Earnings Call May 10, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Avadel Pharmaceuticals plc (AVDL) Q1 2021 Earnings Call Transcri...
Avadel Pharmaceuticals plc (AVDL) Q1 2021 Earnings Conference Call May 10, 2021 8:30 A.M. ET Company Participants Tom McHugh - Chief Financial Officer Greg Divis - Chief Executive Officer Jennifer Gudeman - Vice President of Medical and Clinical Affairs Richard Kim - Chief Commercial Officer ...
Announced FDA acceptance of NDA for once-nightly FT218 and an October 15, 2021 target action PDUFA date Presented positive secondary endpoint data at the AAN 2021 Annual Meeting, which further highlights the overall clinical value proposition of FT218 FT218 launch prepar...
DUBLIN, Ireland, April 29, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate designed to treat excessive daytime sleepiness and cataplexy in patients with narcolepsy, anno...
Secondary endpoint data for once-nightly FT218 further supports previously announced topline data demonstrating clinically meaningful results at 6 g, 7.5 g, and 9 g doses DUBLIN, Ireland, April 17, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company foc...
DUBLIN, Ireland, April 08, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, today annou...
DUBLIN, Ireland, March 18, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced t...
Image source: The Motley Fool. Avadel Pharmaceuticals plc (NASDAQ: AVDL) Q4 2020 Earnings Call Mar 9, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Avadel Pharmaceuticals plc (AVDL) Q4 2020 Earnings Call Transcrip...
Start Time: 08:30 End Time: 09:25 Avadel Pharmaceuticals plc (AVDL) Q4 2020 Earnings Conference Call March 09, 2021, 08:30 AM ET Company Participants Greg Divis - CEO Thomas McHugh - CFO Richard Kim - Chief Commercial Officer Jennifer Gudeman - VP of Medical and Clinical Affairs Conference Ca...
News, Short Squeeze, Breakout and More Instantly...
Avadel Pharmaceuticals plc Company Name:
AVDL Stock Symbol:
NASDAQ Market:
Avadel Pharmaceuticals plc Website:
DUBLIN, June 27, 2024 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, announced today that it is set to join the broad-market Russell 3000 ® Index at the conclusion of the 2024 Russell US Ind...
2024-05-29 06:50:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– 11 accepted abstracts, including new data reiterating satisfaction, preference and clinical benefit of LUMRYZ – – Presentations highlight Avadel’s continued commitment to address gaps in narcolepsy care – DUBLIN, May 22, 2024 (GLOBE NEWSWIRE) -...